Mobile Site ›
Print Friendly View

Test ID: EPIEC    
Epilepsy, Autoimmune Evaluation, Spinal Fluid

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of <2 years

 

Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:

-Psychiatric accompaniments (psychosis, hallucinations)

-Movement disorder (myoclonus, tremor, dyskinesias)

-Headache

-Cognitive impairment/encephalopathy

-Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency) or “multiple sclerosis”

-History of cancer

-Smoking history (20+ pack years) or other cancer risk factors

-Investigating seizures occurring within the context of a subacute multifocal neurological disorder without -obvious cause, especially in a patient with past or family history of cancer

Profile Information A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test IDReporting NameAvailable SeparatelyAlways Performed
AEPCIEpilepsy, Interpretation, CSFNoYes
NMDCCNMDA-R Ab CBA, CSFNoYes
VGKCCVGKC-complex Ab IPA, CSFNoYes
GD65CGAD65 Ab Assay, CSFYesYes
GABCCGABA-B-R Ab CBA, CSFNoYes
AMPCCAMPA-R Ab CBA, CSFNoYes
ANN1CAnti-Neuronal Nuclear Ab, Type 1NoYes
ANN2CAnti-Neuronal Nuclear Ab, Type 2NoYes
ANN3CAnti-Neuronal Nuclear Ab, Type 3NoYes
AGN1CAnti-Glial Nuclear Ab, Type 1NoYes
PCA2CPurkinje Cell Cytoplasmic Ab Type 2NoYes
PCTRCPurkinje Cell Cytoplasmc Ab Type TrNoYes
AMPHCAmphiphysin Ab, CSFNoYes
CRMCCRMP-5-IgG, CSFNoYes

Reflex Tests Lists test(s) that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial test(s)

Test IDReporting NameAvailable SeparatelyAlways Performed
WBNCParaneoplas Autoantibody WBlot,CSFNoNo
CRMWCCRMP-5-IgG Western Blot, CSFNoNo
ABLTCAmphiphysin Western Blot, CSFNoNo
NMOCCNMO/AQP4-IgG CBA, CSFYesNo
AMPICAMPA-R Ab IF Titer Assay, CSFNoNo
GABICGABA-B-R Ab IF Titer Assay, CSFNoNo
NMDICNMDA-R Ab IF Titer Assay, CSFNoNo
PCA1CPurkinje Cell Cytoplasmic Ab Type 1NoNo

Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.

If indirect immunofluorescence assay (IFA) (ANN1C, ANN2C, ANN3C, PCA2C, PCTRC, AMPHC, CRMC, AGN1C) is indeterminate, then paraneoplastic autoantibody Western blot is performed at an additional charge.

If client requests or if IFA patterns suggest CRMP-5-IgG, then CRMP-5-IgG Western blot is performed at an additional charge.

If IFA patterns suggest amphiphysin antibody, then amphiphysin Western blot is performed at an additional charge.

If IFA pattern suggest NMO/AQP4-IgG, then NMO/AQP4-IgG CBA is performed at an additional charge.

If IFA pattern suggest AMPA-Receptor antibody and AMPA-Receptor antibody CBA is positive, then AMPA-Receptor antibody IF titer assay is performed at an additional charge.

If IFA pattern suggest GABA-B-Receptor antibody and GABA-B-R Receptor Ab antibody is positive, then GABA-B-R Receptor Ab antibody IF titer assay is performed at an additional charge.

If IFA pattern suggest NMDA-Receptor antibody and NMDA-Receptor Ab antibody CBA is positive, then NMDA-Receptor Ab antibody IF titer assay is performed at an additional charge.

If IFA patterns suggest PCA-1, then Purkinje Cell Cytoplasmic antibody Type 1 assay is performed at an additional charge.

 

Western Blot:

1. Native neuronal antigens: performed to confirm neuronal nuclear and cytoplasmic Ab specificities when IF screening is uninterpretable.

2. Recombinant human collapsin response-mediator protein-5: performed to confirm CRMP-5-IgG when IF screening is uninterpretable. Also performed for more sensitive detection of CRMP-5-IgG.

 

See Epilepsy Autoimmune Evaluation Algorithm, Spinal Fluid in Special Instructions

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

ANN1C, ANN2C, ANN3C, AGN1C, PCA1C, PCA2C, PCTRC, AMPHC, CRMC, AMPIC, GABIC, NMDIC: Indirect Immunofluorescence Assay (IFA)

AMPCC, GABCC, NMDCC: Cell-Binding Assay (CBA)

GD65C: Immunoprecipitation Assay

VGKCC: Radioimmunoassay Assay (RIA)

WBNC, CRMWC, ABLTC: Western Blot

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

Epilepsy-Autoimmune Evaluation, CSF

Aliases Lists additional common names for a test, as an aid in searching

Anti-Neuronal Nuclear Ab, Type 1
Anti-Neuronal Nuclear Ab, Type 2
Anti-Neuronal Nuclear Ab, Type 3
Anti-Glial Nuclear Ab, Type 1
Purkinje Cell Cytoplasmic Ab Type 2
Purkinje Cell Cytoplasmic Ab Type Tr
Amphiphysin Ab
CRMP-5-IgG
AMPA-R Ab CBA
GABA-B-R Ab CBA
NMDA-R Ab CBA
Glutamic Acid Decarboxylase (GAD65)
VGKC-complex Ab IPA
Seizures
Spells